Manufacturer
Aurobindo Pharma Limited (Unit III),
Contents
Bisoprolol fumarate
Indication
Stable chronic heart failure w/ reduced systolic left ventricular function in addition to ACE inhibitors, diuretics & optional cardiac glycosides. 5 & 10 mg: HTN, CHD (angina pectoris).
Instruction
May be taken with or without food: Swallow whole, do not chew.
Drug interaction
Profound hypotension & AV block w/ verapamil- & diltiazem-type Ca antagonists. Decreased central sympathetic tonus w/ centrally acting antihypertensive drugs eg, clonidine, methyldopa, moxonodine, rilmenidine. Increased risk of hypotension w/ dihydropyridine-type Ca antagonists eg, nifedipine, antihypertensive agents & other drugs w/ BP-lowering potential eg, TCAs, barbiturates, phenothiazines. Potentiated AV conduction time & increased negative inotropic effect w/ class I antiarrhythmic drugs eg, disopyramide, quinidine. Potentiated AV conduction time w/ class III antiarrhythmic drugs eg, amiodarone. Additive systemic effects w/ topical β-blockers. Increased AV conduction time & risk of bradycardia w/ parasympathomimetic drugs. Intensified blood sugar-lowering effect w/ insulin & oral antidiabetics. Attenuated reflex tachycardia & increased risk of hypotension w/ anaesth agents. Reduced heart rate & increased AV conduction time w/ digitalis glycosides. Reduced hypotensive effects by NSAIDs. Reduced effects w/ β-sympathomimetic agents eg, isoprenaline, dobutamine. Increased BP & exacerbated intermittent claudication w/ β- & α-adrenoceptors eg, noradrenaline & adrenaline. Severe postural hypotension w/ moxisylyte. Increased risk of bradycardia w/ mefloquine. Enhanced hypotensive effects w/ MAOIs (except MAO-B inhibitors).
Malaysia
